Biomarker for Farber Disease (BioFarber)
Learn more about:
Related Clinical Trial
PREDIGA 2: Spanish Acronym of “Educational and Diagnostic Project for Gaucher and ASMD”
Incentive Spirometry and Upper Abdominal Laparoscopic Surgery
An Observational Study in Patients With Unexplained Splenomegaly
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Biomarker for Farber Disease (BioFarber)
Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Biomarker for Sly Disease (MPS VII) (BioSly)
Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination
CINC424A2X01B Rollover Protocol
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department
Spleen Size in Peripheral Blood Stem Cell Donors
Estimation of Spleen by Residents With VScan
Ultrasound Estimation of Spleen Size